Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
VANCOUVER, British Columbia, May 02, 2018 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, announced today that David Main, President & CEO, will provide a corporate update at the upcoming Deutsche Bank 43rd Annual Healthcare Conference in Boston on Wednesday, May 9th 2018.
Aquinox Presentation Details
Date: Wednesday, May 9th 2018
Time: 6:20 am Pacific Time / 9:20 am Eastern Time
Location: Boston, MA – Intercontinental Hotel Boston
A live webcast and archive of the event will be available at:
https://edge.media-server.com/m6/p/oiye7bcp
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics for chronic urological conditions marked by inflammation and pain. Aquinox's lead drug candidate, rosiptor (AQX-1125), is in Phase 3 development for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS), a condition for which there are currently few FDA approved and/or effective treatment options. Aquinox is focused on leveraging its library of novel compounds that activate SHIP1 to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Brendan Payne
Associate Director, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.901.3019
[email protected]
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
[email protected]
